🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HR+/HER2- Advanced or Metastatic Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy NCT06998108Phase 31 site📍 Beijing BeBetter Med Inc · Tests: BEBT-209 capsules, BEBT-209 Placebo capluses, Fulvestrant Injection Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer NCT05744687Phase 2, Phase 39 sites📍 Fuzhou📍 Guangzhou📍 Guiyang Shanghai Pharmaceuticals Holding Co., Ltd · Tests: SPH4336 Tablets 400mg, SPH4336 Tablets Placebo A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites📍 Bengbu📍 Hefei📍 Hefei Genor Biopharma Co., Ltd. · Tests: GB491 combined with Letrozole, Placebo combined with Letrozole Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer NCT07205822Phase 340 sites📍 Largo📍 Fort Wayne📍 Omaha AstraZeneca · Tests: Dato-DXd Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer NCT06642545Phase 21 site📍 Beijing RemeGen Co., Ltd. · Tests: Disitamab Vedotin, RC148, Albumin-bound Paclitaxone, Toripalimab Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505Phase 11 site📍 Adelaide SAPU NANO (US) LLC · Tests: Sapu003, Exemestane 25 MG Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959Phase 31 site📍 Beijing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China NCT07476170n/a1 site📍 Bingjie Novartis Pharmaceuticals A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy NCT05646862Phase 3210 sites📍 Greenbrae📍 Los Alamitos📍 Los Angeles Hoffmann-La Roche · Tests: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors NCT07767474Phase 1, Phase 26 sites📍 Fort Worth📍 Houston📍 San Antonio Antares Therapeutics, Inc · Tests: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898 T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd NCT07683754Phase 35 sites📍 Columbia📍 Las Vegas📍 Nashville Daiichi Sankyo · Tests: Trastuzumab deruxtecan, Trastuzumab, Pertuzumab, Endocrine Therapy, Palbociclib A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites📍 Duarte📍 Grand Rapids📍 Long Island City Pfizer · Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer NCT07461454Phase 31 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202, Eribulin, Capecitabine, Gemcitabine, Vinorelbine To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer NCT07368998Phase 234 sites📍 Los Angeles📍 Jacksonville📍 Kansas City Hoffmann-La Roche · Tests: Inavolisib, Fulvestrant Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM NCT06974604Phase 21 site📍 Providence Brown University · Tests: Dexamethasone oral A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites📍 Beijing📍 Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC NCT06439771Phase 21 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202 should be intravenously infused Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer NCT05860465Phase 2, Phase 322 sites📍 Guangzhou📍 Liuzhou📍 Anyang Shanghai Pharmaceuticals Holding Co., Ltd · Tests: SPH4336 Tablets, SPH4336 Tablets Placebo Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer NCT05318469Phase 1, Phase 21 site📍 Los Angeles Yuan Yuan · Tests: Ivermectin, Balstilmab, Pembrolizumab A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer NCT06383767Phase 31 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice) Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites📍 Aviano📍 Brescia📍 Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Palbociclib, Ribociclib, Abemaciclib Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors NCT05969041Phase 16 sites📍 Darlinghurst📍 Randwick📍 Westmead Myeloid Therapeutics · Tests: MT-302 (A) A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors NCT06827613Phase 1, Phase 28 sites📍 Los Angeles📍 Los Angeles📍 Boston Marengo Therapeutics, Inc. · Tests: STAR0602, Sacituzumab Govitecan (SG) Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer NCT06515470Phase 16 sites📍 Rochester📍 Omaha📍 Houston Biotheryx, Inc. · Tests: BTX-9341, Fulvestrant, BTX-9341
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy